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ABSTRACT
Previous research in rodents and humans has implicated the ventral hippocampus in
regulating anxiety. However, many rodent studies examining ventral hippocampal
neuronal pathways have utilized lesions that create nonspecific and/or nonreversible
damage to the region. The present study sought to characterize the role of ventral
hippocampal glutamatergic pyramidal neurons in modulating anxiety-like behavior during
exposure to a variety of threatening stimuli. Five weeks prior to testing, male Long-Evans
hooded rats received ventral hippocampal viral-vector infusions expressing either pAAVCaMKIIα-hM4D-mCherry (DREADD) or pAAV-CaMKIIa-EGFP (GFP). DREADD
transfection allowed for the specific, noninvasive and temporary inhibition of ventral
hippocampal glutamatergic neurons immediately before threat presentation. Rats were
evaluated for behaviors congruent with anxiety- or fear-like defensive states (e.g., freezing,
risk assessment, avoidance, etc.) during testing in the elevated plus-maze and light-dark
exploration test, or footshock-induced contextually conditioned fear, respectively.
Analyses revealed a significant effect of DREADD inhibition that was dependent on the
type of threat exposure. Specifically, compared to GFP controls, DREADD-induced
silencing of ventral hippocampal glutamatergic neurons reduced anxiety-like behavior in
the elevated plus-maze and light-dark test, without reliably affecting the expression of
conditioned fear. The present results confirm that ventral hippocampal glutamatergic
pyramidal neurons are recruited in rats during exposure to anxiety-inducing stimuli. These
iii

data add to a growing literature implicating the ventral hippocampus as a key region
involved in modulating anxiety-like behaviors in rodents, primates and humans.
Keywords: Designer receptor exclusively activated by designer drugs (DREADDs),
Ca2+/calmodulin dependent kinase II, glutamatergic pyramidal neuron, defense.
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CHAPTER 1 INTRODUCTION
Normal and Abnormal Stress
The continued improvement in efficacy of psychopharmaceuticals relies, at least
fractionally, on advancing our understanding of the interplay between pathological
behavior

and

the

underlying

neurobiology.

Some

of

the

most

debilitating

psychopathologies involve altered neural systems that regulate stressor-induced behaviors
during anxiety- and fear-like defensive states. Normally this biobehavioral response is
healthy and adaptive allowing prey animals to avoid predation through threat detection
(e.g., risk assessment) and threat avoidance (e.g., flight, freezing; Blanchard and
Blanchard, 2003). This same adaptive response to stressors in humans facilitates the
maintenance of allostasis and prevents the detrimental effects of a prolonged allostatic load
(McEwen, 2003). However, when dysregulated, this process contributes to the
manifestation of several psychopathologies commonly termed anxiety/stress disorders (de
Kloet, 2003) that include generalized anxiety disorder, panic disorder, agoraphobia,
specific phobias, social anxiety, obsessive compulsive disorder and post-traumatic stress
disorder (American Psychiatric Association, 2013). Globally, an estimated 264 million
people, or 3.6% of the population currently have an anxiety disorder (WHO, 2017) with an
estimated cost of more than US$ 1.15 trillion annually (Chisolm et al., 2016). In order to
improve current pharmacotherapies, future research is needed to delineate the precise roles
of distinct neuronal populations in mediating stressor-induced anxiety- and fear-like
defensive states.
Neurobiology of Defense
The neurobiology of defensive behavior has been explored extensively in the
literature and has evolved enormously from the original “fight or flight” acute stress
response construct (Cannon, 1915). The mammalian biological stress response is regulated
by two intimately connected systems; the sympathetic-adrenomedullary (SAM;
Frankenhaeser, 1986) system and the hypothalamic-pituitary-adrenocortical (HPA;
Stratakis et al., 1995) system. Although these two systems are controlled primarily by the
hypothalamus (for review, see Herman et al., 2005), regulation of stressor-induced anxiety
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and fear behaviors recruit additional limbic circuits including the hippocampus, amygdala,
as well as the medial and orbital prefrontal cortices (Gross & Canteras, 2012)). Initially,
Klüver and Bucy (1939) implicated these regions as key structures controlling general
defensive behavior when they observed that temporal lobectomies encompassing the
amygdala, hippocampus and adjacent cortices produce robust behavioral alterations in
rhesus monkeys. Subsequent studies reported that inhibition of the amygdala generally
reduces conditioned fear-like behaviors in monkeys (Weiskrantz, 1956), rodents
(Blanchard and Blanchard, 1972; LeDoux et al., 1988; Liang et al., 1992; Maren et al.,
1996; Tovote et al., 2016) and humans (Terburg et al., 2012; Klumpers et al., 2015;
Shackman and Fox, 2016; for general review see Phelps and LeDoux, 2005; or Tovote,
Fadok and Lüthi, 2015). These findings are complimented by human functional
neuroimaging studies that reveal amygdala activation during the presentation of unmasked
and masked fearful visual stimuli (Morris et al., 1996; Whalen et al., 1998; Morris et al.,
1999). Taken together these results indicate a critical role for the amygdala in emotional
processing, particularly the expression of conditioned fear.
Septotemporal Segregation of Hippocampal Function
Historically, the pedagogy of the hippocampus has focused on spatial navigation
(O’Keefe and Nadel, 1978; Morris et al., 1982), and specific forms of learning and memory
(Larson and Lynch, 1986; Squire and Zola-Morgan, 1991). However, it is also undeniable
that the hippocampus is involved in modulating specific anxiety-like behaviors (for review
see Gray and McNaughton, 2000; Canteras et al., 2009; Strange et al., 2014). Indeed, Gray
and McNaughton (2000) reported that all anxiolytic drugs modulate the behavioral
inhibition system, the canon component of which is the septo-hippocampal system. These
findings lead to their septo-hippocampal theory of anxiety that marked a clear distinction
between fear (controlled primarily by the amygdala) and anxiety (controlled primarily by
the septo-hippocampal system), and defined conflicting goals as the primary input to this
system (Gray and McNaughton, 2000; McNaughton and Corr, 2004).
Lesions of the vHC
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Studies performing site specific hippocampal manipulations have revealed a
functional differentiation across the septotemporal axis (Risold and Swanson, 1996; Moser
and Moser, 1998; Kheirbek et al, 2013), with the dorsal pole of the hippocampus (dHC)
involved in various forms of memory (e.g., spatial, episodic, etc.) and the ventral pole of
the hippocampus (vHC) involved in emotional regulation (for review see Fanselow and
Hong-Wei, 2010; Kheirbek et al., 2013; Strange et al., 2014). For instance, Bannerman et
al. (2002) found a double dissociation where NMDA lesions of the vHC but not dHC
reduce anxiety-like behaviors in rats in three classic tests of anxiety [social interaction,
elevated plus-maze (EPM), and hyponeophagia], while dHC but not vHC lesions produce
deficits in working and spatial memory (T-maze and Morris water task). Pentkowski et al.
(2006) observed that pretraining ibotenic acid vHC lesions reduce unconditioned anxietylike behaviors in rats exposed to cat odor, but not a live cat, effects indicating a specific
vHC role in regulating anxiety- but not fear-like defensive states. Importantly, matched
lesions of the dHC had no effect on the expression of unconditioned anxiety-like defensive
behaviors in these paradigms (Pentkowski et al., 2006). Similarly, rats with vHC, but not
dHC, lesions fail to avoid the open arms of an elevated t-maze (Trivedi and Coover, 2004),
and exhibit reduced measures of anxiety in the social interaction, light-dark (LDT),
hyponeophagia and successive alley tests (McHugh et al., 2004). A reduction in
unconditioned anxiety-like behaviors has also been observed in the EPM following vHC
lesions/inactivation using lidocaine (Bertoglio et al., 2006), ibotenic acid (Kjelstrup et al.,
2002), tetrodotoxin (Degroot and Treit, 2004) and electrolytic (Trivedi and Coover, 2004)
procedures. Taken together, these finding clearly highlight the vHC, but not dHC, as the
pivotal contributor in Gray and McNaughton’s (2000) septo-hippocampal theory of
anxiety.
Receptor Manipulations in the vHC
Micro-infusion studies targeting specific receptor systems further implicate the
vHC in the expression of untrained defensive behaviors in response to anxiety-inducing
stimuli (for review, Engin & Treit, 2007). Briefly, infusion of glutamate antagonists (Zhang
et al, 2001; Hackl, Nascimento, and Carobrez, 2007; Marrocco et al., 2012), GABAA
agonists (Bast et al., 2001; Trent and Menard, 2010; McEown and Treit, 2010, 2013; Zhang
3

et al., 2014), acetylcholine agonists (Degroot and Treit, 2002), nitric oxide (Calixto et al.,
2010) and mineralocorticoid antagonists (McEown and Treit, 2011) all attenuate
unconditioned anxiety-like behaviors in tasks including the EPM, shock-probe burying
test, open field test, elevated T-maze, and LDT. Additionally, Pentkowski et al. (2009),
reported bidirectional modulation of unconditioned anxiety-like behaviors in response to
cat odor following micro-infusions of either a CRF1 antagonist (decrease) or agonist
(increase). Collectively, these micro-infusion experiments further indicate that vHC
neuronal activity is required for the expression of anxiety-like defensive responses.
Genetic Manipulations of the vHC
Contemporary optogenetic and chemogenetic techniques have been developed to
target specific cellular populations with anatomical and temporal specificity. Using
optogenetics in mice, a recent study observed that direct inhibition of neurons projecting
from the vHC to the medial prefrontal cortex (mPFC) decreases avoidance of the open arms
in the EPM (Padilla-Coreano et al., 2016). Similarly, Morrone-Parfitt and colleagues
utilized chemogenetics to elucidate the bidirectional control of anxiety-like behaviors by
distinct vHC cell populations in the mouse. Specifically, activation of vHC neurons
projecting to the lateral septum attenuated anxiety-like behaviors in EPM and a novelty
suppressed-feeding task, while inhibition of this same cellular population enhanced
anxiety-like behaviors (Morrone-Parfitt et al, 2017). These researchers also observed an
increase in anxiety-like behaviors following selective activation of mPFC projecting vHC
cells. Lastly, optogenetic activation of vHC projections to the lateral hypothalamic area
increased anxiety-like behavior in mice (Jimenez et al., 2018). Collectively, these results
indicate that anxiety-like behaviors in mice are controlled via the dynamic balance of
signals arising from the vHC.
vHC Implicated in Conditioned Defense
In addition to modulating the expression of innate anxiety-like behaviors in
response to threatening stimuli, research also implicates the vHC in modulating
conditioned defensive behaviors. Following post training electrolytic lesions of the vHC,
but not dHC, Trivedi and Coover (2004) observed a reduction in cue and contextual
4

conditioned freezing. In addition, Pentkowski et al. (2009) found bidirectional modulation
of conditioned defensive behaviors during contextual re-exposure to a cat odor paired
environment, where CRF1 agonism and antagonism potentiated and attenuated defensive
behaviors respectively. Similarly, pre-training ibotenic acid lesions of the vHC attenuated
the expression of conditioned behaviors elicited by exposure to either cat odor-, live cator footshock-paired environments (Pentkowski et al., 2006). This effect was not detected
during exposure to a live cat consistent with the notion that the vHC is selectively recruited
during exposure to anxiety-inducing potential threats such as predator odors or conditioned
contexts, rather than fear-inducing threats like a live predator (Fanselow & Lester, 1988;
Blanchard & Blanchard, 1990; Kjelstrup et al., 2002). Using optogenetics, Jimenez et al.
(2018) found that stimulation of vHC terminals in the basolateral amygdala impair
footshock-indued contextual fear conditioning. Collectively these findings ascribe a roll
for the vHC in regulating the expression of conditioned anxiety-like defensive behaviors
to potentially threatening stimuli.
Purpose of study. The present study sought to replicate and extend the work by PadillaCoreano et al. (2016), Morrone-Parfitt et al. (2017) and Jimenez et al. (2018) in the mouse
by using chemogenetic techniques to investigate the functional role of glutamatergic vHC
afferent neurons in regulating the expression of anxiety- and fear-like defensive behaviors
in the rat. These techniques allowed us to selectively silence vHC glutamatergic neurons
immediately before threat exposure. Based on the aforementioned previous work in the
mouse, we predicted that silencing glutamatergic vHC neurons in the rat would attenuate
anxiety-like behaviors associated with the presentation of scenarios where the potential for
predation was possible, but not explicit. This work adds to the growing literature defining
the function of the hippocampal complex, specifically the role of the vHC in innate and
learned anxiety-like defensive behaviors.
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CHAPTER 2 MATERIALS AND METHODS
Animals
Subjects were 20 male Long-Evans hooded rats bred and shipped from Charles
River Laboratories (Charles River, USA). Upon arrival to the Department of Psychology
Animal Research Facility at the University of New Mexico, rats were pair housed and
maintained at a constant temperature (23 ℃) and diurnal cycle (12 h light/dark, lights on
at 1000 h) with food and water available ad libitum. Rats weighed between 320 and 475 g
at the time of surgery. All husbandry and procedures adhered to the Guide for the Care and
Use of Laboratory Animals (National Research Council, 2011), and all experimental
procedures were reviewed and approved by the University of New Mexico Institutional
Animal Care and Use Committee.
Viral Vectors
In order to characterize the function of distinct vHC neuronal pathways, rats
received viral vector infusions into the vHC to express designer receptors exclusively
activated by designer drugs (DREADDs). Specifically, a pAAV-CaMKIIα-hM4DmCherry vector system was used to selectively and temporarily silence vHC neuronal
firing by inhibiting G-protein coupled receptor signaling (Dobrzanski et al 2017, Zou et al
2016 and Roth 2016). The CaMKIIα promotor allowed for the selective inhibition of vHC
glutamatergic neurons, without altering cholinergic or GABAergic neuronal activity (Liu
& Jones, 1996; Sík, et al., 1998), as CaMKIIα within the HC selectively colocalizes within
glutamatergic neurons (Wang, et al., 2013). Additionally, pAAV-CaMKIIa-EGFP viral
vectors were infused as viral controls. Viral vectors were obtained from the University of
North Carolina at Chapel Hill Vector Core.
Surgery
Prior to surgery, rats were handled 4-5 times per week for three weeks to minimize
stress. Rats were randomly assigned to receive either DREADD (n = 15) or GFP control
(n = 5) viral infusions. Prior to surgery, rats were deeply anesthetized using 4% isoflurane
and received an injection of buprenorphine (0.1mg/kg/ml, s.c.) to alleviate pain; aesthesia
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was maintained throughout surgery at 1.5-2% (SomnoSuite® Low-Flow Anesthesia
System, Kent Scientific). Next rats were placed into a stereotaxic apparatus (David Kopf
Instruments) and received a 0.1ml injection of 2% lidocaine (s.c., Sparhawk Laboritories,
2016) under the scalp to provide local anesthesia before the surgical incision. A set of small
holes (0.5 mm in diameter) were drilled bilaterally into the skull to allow for the insertion
of a 10 μl micro syringe (Hamilton). Rats received two pairs of bilateral infusions within
the intermediate and ventral regions of vHC using coordinates obtained from Paxinos and
Watson (2012) and based on previous protocols (Pentkowski et al., 2006; 2009): ventral (5.2 mm posterior to bregma, ±5.1 from midline and -7.1 ventral from the surface of the
skull); and intermediate (-5.2 mm posterior to bregma, ±5.1 from midline and -6.0 ventral
from the surface of the skull). Following each infusion (0.2μl/min; 1μl/site) the syringe
remained in place for 5 additional min to allow for complete viral diffusion. Following
surgery, rats received a nonsteroidal anti-inflammatory (Enfrolax® 100; Norbrook
Laboritories, 2016) in their water for 3 days and were singly housed for 7 days before being
reunited with their original cage mate. In order to insure complete viral expression, the
virus incubated for 5 weeks before behavioral testing commenced.
Drugs
Agonists for the DREADDs [clozapine-N-oxide (CNO) and clozapine; Tocris
Bioscience] were dissolved in a 0.9% sterile saline solution. Prior to testing in the EPM,
rats assigned to the agonist group received injections of CNO (1mg/kg/ml, i.p.), while rats
assigned to the agonist group on footshock and LDT test days received clozapine (0.1
mg/kg/ml, i.p.). CNO injections were delivered 20 minutes prior to each trial and clozapine
injections were administered 30 min prior to each trial; matched saline control injections
were administered using the same volume and route of injection. Thus, for each test type
the following three experimental groups were obtained: DREADD/agonist (vHC
inhibition, n=10), DREADD/saline (viral control; n=5) and GFP/agonist (agonist control;
n=5). Dosage and injection schedules were based on previous work demonstrating that
CNO can be reverse metabolized to clozapine and produce clozapine-like interoceptive
stimulation at doses larger than 1mg/kg after 30 min (Gomez et al., 2017; Manvich et al.,
2018). Both agonist compounds were utilized to determine if the same behavioral effect
7

could be achieved with both compounds using different tests of anxiety to rule out possible
reverse metabolism as a confound.
Behavioral Testing
All behavioral testing occurred between 1000 and 1400 h in the following order:
EPM, footshock-induced contextual fear conditioning and LDT; each test was separated
by 7-12 days to prevent potential additive effects of stress and to prevent agonist
accumulation between tests. Anxiety- and fear-like defensive behaviors were analyzed
during exposure to a potentially threatening environment (EPM and LDT) as well as
immediately following threat exposure (post footshock). Additionally, a contextual
conditioned test was performed 24 h after initial footshock exposure. Each apparatus was
cleaned using a 10% ethanol solution between trials.
Behavioral Measures
Anxiety- and fear-like defensive behaviors are species typical and situation specific
(Bolles, 1970; Blanchard and Blanchard, 1989). Although the defensive states of anxiety
and fear are related, they are discrete categories, elicited by specific conditions, and
represented by unique sets of behaviors (Perusini & Fanselow, 2015). Indeed, anxiety- and
fear-like defensive states are so closely related that the terms are often mistakenly used
interchangeably, identical behavioral indices are used to measure them, or one term is used
to define the other. Even the Diagnostic and Statistical Manual of Mental Disorders, 5th ed.
(DSM-V; American Psychology Association, 2013) lists the essential characteristic of
agoraphobia, an anxiety disorder, as the “intense fear of any place or situation where escape
might be difficult.” This lack of consistency throughout the literature hinders the translation
between clinical practice and pre-clinical research. In order to avoid this ambiguity, the
present study adopted the Predator Imminence Model (Fanselow & Lester, 1988). This
model defines the antecedent causes (pre-encounter, post-encounter and circa-strike) and
elicited behaviors (risk assessment, freezing, biting, etc.) that differentiate anxiety from
fear, and in a more recent review was demonstrated to align with the National Institute of
Mental Health’s adoption of the Research Domain Criteria (for review see, Perusini &
Fanselow, 2015). Thus, the EPM and LDT were utilized to simulate pre-encounter
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situations that elicit anxiety-like behavior characterized by changes in exploratory and risk
assessment behaviors. In contrast footshock conditioning and contextual re-exposure were
used as an analogue for post-encounter situations that elicit fear, characterized
predominantly by freezing in rodents (Blanchard and Blanchard, 1969). The post footshock
and contextual fear conditioning trials measured levels of freezing—complete cessation of
movement other than respiration. During the EPM and LDT trials, measures included: head
outs—extension of the head out of the closed arm (EPM) or dark compartment (LDT)
without exciting the location; transits—crossing from one chamber into the other chamber
of the apparatus (LDT), or the number of open and closed arm entries (EPM), measured as
all four paws moving from one marked section of the apparatus to another; and
avoidance—duration of time spent in the dark compartment (LDT), or the percentage of
time spent in the closed versus open arms (EPM). Additional behavioral measures scored
in the EPM test included: head dips—extension of the subject’s head over the edge of an
open arm; and risk assessment—combined measure of both stretch approach—forward
ambulation with flat back and stretched neck and stretch attend—standing on all four paws
with flat back and stretched neck orientated toward the threat source. Behavioral measures
represent the durations of events in seconds, numbers of transits, or percentages of total
time in a 5 min observation period for each test.
Elevated Plus-maze
All sessions were conducted under red light. The EPM apparatus consisted of four
Plexiglas arms arranged to form a plus, elevated 75 cm above the floor. Each arm was 10
cm wide and 50 cm long, and each arm was joined at the center by a 10 cm square platform.
The two opposite “open” arms contained no walls, while the other two “closed” arms had
40 cm high side walls. The front panel of each enclosed arm was made of clear Plexiglas
to allow for observation and recording. Twenty min prior to testing, control [n=10;
GFP/CNO (n=5) and DREADD/saline (n=5)] and experimental (n=10; DREADD/CNO)
rats received their assigned injections and were placed in the center of the apparatus facing
one of the closed arms.
Footshock
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All sessions were conducted under dim, white light. The footshock apparatus
consisted of a Plexiglas/metal enclosed chamber (Coulbourn Instruments; 30 x 25 x 30 cm)
with a clear front panel to permit recording. Test chambers were equipped with a metal bar
floor that was connected to a manual precision animal shocker (Coulbourn Instruments).
On unconditioned test days all rats received their assigned injections 30 min prior to the
start of their test trial: control [n=10; GFP/clozapine (n=5) and DREADD/saline (n=5)] and
experimental (n=10; DREADD/clozapine) rats. Once the trial commenced, rats were
allowed to explore the apparatus for 3 min before receiving three 1mA scrambled
footshocks administered 1 min apart; fear-like defensive behaviors were measured for 5
min following the administration of the final shock (post footshock test). Rats were
returned to the same test chamber 24h after the unconditioned test trial for a contextual
conditioned test trial. No injections were administered on the conditioned test day.
Light/dark Test
All sessions were conducted under dim, white light. The LDT apparatus consisted
of two adjacent Plexiglas compartments (30 x 30 x 60 cm), one was white with no top and
one was black with a black lid to prevent light entry. The light and dark compartments were
separated by a Plexiglas wall that had white on one side and black on the other, with an
open partition that allowed for the animal to freely move from one side to the other. The
apparatus was positioned so that the white compartment was centered below an overhead
light source. Thirty min prior to testing, control [n=10; GFP/clozapine (n=5) and
DREADD/saline (n=5)] and experimental (n=10; DREADD/clozapine) rats received their
assigned injections and were placed in the dark compartment of the apparatus.
Histology
Following completion of behavioral testing, histological verification of viral
expression was performed. Rats were deeply anesthetized with Fatal Plus (1ml/kg, i.p.) and
were perfused transcardially with a 0.1M ice cold phosphate buffered saline followed by
fresh ice cold 4% paraformaldehyde. Following extraction, brains were placed in 4% PFA
for 24h before being transferred to a 15% sucrose solution for cryoprotection. The brains
remained in this solution until they visibly sank (approximately 24h) and then were
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transferred to a 30% sucrose solution where they remained (at least 24h) until sectioning
on a cryostat (Thermo Scientific). A series of coronal sections (40 μm) were collected
throughout the entire anterior-posterior range of the dHC and vHC and were stored in a
cryoprotectant solution until immunostaining.
Immunohistochemistry
In order to confirm localized vHC viral expression, sections from each DREADDinfused rat were immunostained for mCherry; GFP was visualized without immunostaning.
Free-floating sections were first washed in 0.1M PB to remove the cryoprotectant followed
by 50mM ammonium chloride. Next, the tissue was soaked in PB containing 5% normal
goat serum (NGS; Vector Laboratories, Burlingame, CA) and 0.3% Triton X-100 followed
by a 48h incubation in the mouse monoclonal anti-mCherry serum (1:500, Abcam,
ab125096) containing 0.1% bovine serum albumin (Sigma, a9647) 3% NGS, and 0.3%
Triton X-100. Subsequently, the tissue was washed in PB and incubated for 2h at room
temperature with the biotinylated goat anti-mouse AlexaFlour-594-labeled antibody
(1:500, Thermo Fisher Scientific, A21145). Next, sections were washed in PB and coverslipped with mounting media containing DAPI (Vector, H1200. Slides were analyzed on a
Leica DMRXA2 epifluorescent microscope (Leica) equipped with a mercury lamp for
mCheery and GFP fluorescent imaging. To assess placement and spread of the viral
infusions, sections were compared to a schematic representation from the Paxinos and
Watson brain atlas (2012). Rats with misplaced viral expression or that lacked viral
expression entirely were excluded from the analyses.
Statistics
Independent sample Student’s t-tests and Levine’s tests for equality of variance
were performed on each unconditioned and conditioned dependent measure. Alpha was set
at 0.05 for all comparisons. We predicted there would be no observed differences between
the GFP/CNO/clozapine and the DREADD/saline rats in any behavioral test and therefore
data from these two groups were compared first, with the intention of pooling their data
into one control group. Thus, final statistical comparisons were planned between controls
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(GFP/CNO/clozapine + DREADD/saline) and experimental (DREADD/CNO/clozapine)
rats for each dependent variable.
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CHAPTER 3 RESULTS
Histology

A serial histological reconstruction of the viral-mediated gene expression within
the vHC is shown in Fig. 1. Visual examination of each section revealed that no rat
13

exhibited viral expression outside of the vHC, with expression ranging between -4.36mm
and -5.64mm posterior to bregma. All rats exhibited expression throughout the CA3 field
of the vHC (-4.36mm and -5.64mm posterior to bregma), and within the CA2 and CA1
fields of the vHC (-4.56mm and -4.80mm posterior to bregma). Fluorescently tagged fiber
tracts were observed throughout the oriens layer of the vHC (-4.44mm and -5.52mm
posterior to bregma), and positively marked cells were observed within the pyramidal cell
layer of the vHC (-4.80mm and -5.16mm posterior to bregma) and the granular layer of the
dentate gyrus of the vHC (-5.40mm and -5.64mm posterior to bregma).
Elevated Plus-maze
The
durations

and

frequencies
each

of

dependent

measure

during

testing

in

the

EPM for both the
experimental and
control

groups

are presented in
Fig.

2.

As

predicted,
comparison
between
DREADD/saline
viral-controls and
GFP / CNO /
clozapine
agonist-controls
revealed

no

statistically
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significant differences between their respective scores on any of the behaviors measured
(data not shown). Thus, these groups were pooled into one control group and all subsequent
analysis was performed between the pooled control group (DREADD/saline +
GFP/CNO/clozapine) and the experimental (DREAD/CNO/clozapine) group. One control
rat was removed from this analysis because at least two of its measures deviated by greater
than three standard deviations from the mean. Thus, final statistical analysis for the EPM
was conducted on the nineteen remaining rats. There was a significant increase in both the
percent of open arm time (M=0.7209, SD=0.101) and the number of head dips (M=20.10,
SD=6.35) following vHC chemogenetic inhibition compared to controls (M=0.5737,
SD=0.1066 and M=10.56, SD=5.855); t(17)=-3.088, p < 0.05 and t(17)=-3.393, p < 0.05,
respectively. There was a trend towards a decrease in open arm entries for the inhibition
group; t (17)= 1.852, p=0.098. No significant group differences were detected for head outs
or total risk assessment measures (p > 0.05 in each case).
Footshock
Freezing
durations

for

both the vHCinhibition

and

control rats for
the

post-shock

and context reexposure

test

trials

are

presented

in

Fig. 3. One rat was withheld from this behavioral test due to an injury that inhibited
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locomotion. No significant differences in freezing were detected between groups (p >
0.05).
Light/dark Test
Fig. 4 presents the durations and frequencies of each dependent measure during the
LDT. Two experimental rats were removed from the analysis; one rat escaped the apparatus
during testing and the other rat was removed because it developed an injury prior to test
day that inhibited locomotion. Chemogenetic inhibition of the vHC significantly increased
the number of light entries (M=3.88, SD=1.727) compared to controls (M=1.60,
SD=1.506); t(16)=-2.986, p = 0.05. There was also a significant increase in the duration of
time spent in the light chamber following vHC inhibition (M=93.80, SD=27.735)
compared with controls (M=46.28, SD=50.311); t(16)=-2.543, p < 0.05. No significant
group
differences were
detected

in

latency to enter
the

light

chamber or the
number of head
outs (p > 0.05 in
each case).
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CHAPTER 4 DISCUSSION
vHC Glutamatergic Output Required for Anxiety-Like Behavior in Rats
The present results are the first to describe a unique role for vHC glutamatergic
output neurons in rats as mediators of defensive responses arising from pre-encounter
instances that provoke anxiety-like behaviors, but not post-encounter instances that
provoke fear-like behaviors. This work replicates and extends previous work in mice that
found similar effects on anxiety- but not fear-like behaviors following inhibition of vHC
glutamatergic pathways (Padilla-Coreano et al., 2016; Morrone-Parfitt et al., 2017;
Jimenez et al., 2018), as well as pharmacological antagonism of vHC glutamate receptors
in mice (Zhang et al, 2001) and rats (Hackl, Nascimento, and Carobrez, 2007; Marrocco et
al., 2012; Zhu et al., 2018). Specifically, we observed an increase in exploratory behavior
of novel, potentially threatening environments (EPM and LDT) following chemogenetic
inhibition of vHC glutamate neurons, while post-shock and contextual fear-like behavior
remained unaltered. These observations are consistent with previous literature defining
anxiety and fear as discrete phenomena necessarily controlled by discrete neural pathways
(Blanchard and Blanchard, 1989; Perusini & Fanselow, 2015). These results confirm that
vHC glutamatergic pyramidal neurons are part of the neural circuitry that control defensive
behaviors evoked by anxiogenic stimuli in rats.
The vHC consists of several heterogeneously distributed cell types including
glutamatergic, GABAergic, and cholinergic neurons (Siegel et al., 1994; Freund &
Buzsaki, 1996; Nomura et al, 1997; Spencer & Bland, 2019), and although CAMKIIα has
been shown to selectivity colocalize with glutamatergic neurons (Wang et al., 2013), there
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remains the possibility that this association is not exclusive within the vHC. However,
transgenic and pharmacological inhibition of GABAergic hippocampal interneurons have
resulted in a schizophrenia-like behavioral profile (for review, see Heckers & Konradi,
2015). Likewise, neuroimaging and post-mortem analysis of schizophrenic patients
revealed hippocampal hyperactivity and stark volume reduction due to atrophy of
GABAergic interneurons (Konradi et al, 2001; Benes, F.M., 2015). Furthermore, anxietylike behaviors and the spatial representation of open arm aversion in the EPM, along with
vHC-mPFC theta synchrony are dependent on excitatory, but not inhibitory input from the
vHC (Padilla-Coreano et al., 2016). Similarly, cholinergic cells within the hippocampus
have been repeatedly implicated in facilitating learning and memory through the processes
of long-term potentiation and long-term depression (Ovsepian et al., 2004; for review, see
Palacios-Filardo &Mellor, 2019). We observed no deficits in learning/memory and no
symptoms of psychosis, and therefore we are confident that the results obtained were the
consequence of a glutamatergic-specific manipulation.
Limitations of the Present Study
Several methodological limitations in the present study should be noted. First,
DREADD-induced vHC inhibition only occurred prior to the footshock conditioning trial.
While our data in rats and previous reports in mice (Morrone-Parfitt et al., 2017) suggest
that vHC glutamatergic neurons are not necessary for acquiring post-encounter and
contextual post-encounter fear-like behaviors, we cannot rule out the possibility that these
neurons may be involved in consolidation or recollection processes. Second, our contextual
conditioning environment may not have been complex enough to require a hippocampal
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representation of the environment (Wang et al., 2013), and thus conditioned freezing may
have been driven by the amygdala (Tovote et al., 2016).
Future Directions
In order to further delineate the precise role of the vHC in regulating defensive
behaviors in rats, future studies should examine specific vHC efferent pathways, as well as
additional vHC cell populations. Specifically, studies should explore whether vHC
glutamatergic neurons in rats bi-directionally regulate anxiety-like behaviors via separate
septal and cortical (Morrone-Parfitt et al., 2017) or hypothalamic (Jimenez et al., 2018)
pathways, which have been reported in mice. Similarly, future research is needed to
examine the role of specific connections between the vHC, mPFC, and amygdala (Ishikawa
& Nakamura, 2006; Kim & Cho, 2017) on anxiety- and fear-like defensive behaviors.
Lastly, the effects of chemogenetic and/or optogenetic manipulations of additional vHC
cell types (e.g., GABAergic, cholinergic, etc.) on anxiety- and fear-like behaviors are
needed to fully characterize the role of the vHC in mediating defense.
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